Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[How should ventricular arrhythmia be treated?].

J Widimský1, J Bytesník

  • 1Subkatedra kardiologie ILF, Praha.

Vnitrni Lekarstvi
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics, management, and outcome of infective endocarditis in the Czech Republic: prospective data from the ESC EORP EURO-ENDO registry.

Bratislavske lekarske listy·2021
Same author

The effect of adrenalectomy on exercise response of the renin-angiotensin-aldosterone system and exercise tolerance in primary aldosteronism.

Physiological research·2018
Same author

Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.

Physiological research·2017
Same author

Lower physical fitness in patients with primary aldosteronism is linked to the severity of hypertension and kalemia.

Physiological research·2016
Same author

Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma.

Physiological research·2015
Same author

Inflammatory markers in primary aldosteronism.

Physiological research·2015
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Antiarrhythmic drugs for ventricular arrhythmias post-myocardial infarction do not reduce mortality and may increase risk. Beta-blockers are the only effective treatment for reducing sudden cardiac death in these patients.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Post-myocardial infarction patients often experience ventricular arrhythmias.
  • Existing antiarrhythmic therapies, including Class Ic drugs, have shown limited efficacy in reducing mortality.

Purpose:

  • To review the classification and therapeutic strategies for ventricular arrhythmias in post-myocardial infarction patients.
  • To highlight the proarrhythmic risks associated with antiarrhythmic drug therapy.

Summary:

  • The CAST study demonstrated that antiarrhythmic therapy, even when effective against arrhythmias, does not impact mortality in post-myocardial infarction patients.
  • Class Ic antiarrhythmic drugs (encainide, flecainide) can exhibit proarrhythmic effects, potentially increasing mortality risk.
  • Beta-blockers are identified as the sole drug class significantly reducing sudden death incidence in this patient population.

Related Experiment Videos

Impact:

  • Revising treatment guidelines for ventricular arrhythmias post-myocardial infarction.
  • Emphasizing the critical role of beta-blockers in managing sudden cardiac death risk.
  • Raising awareness of the potential proarrhythmic dangers of certain antiarrhythmic agents.